N -glycosylation of eukaryotic proteins plays roles in protein folding, trafficking, and signal transduction. The biological influence of the process is well understood, whereas the pharmacological impact of protein N -glycosylation is not well under discerned. The role of N -glycosylation on drug binding to protein has been rarely studied. We have modeled the influence of a bi-antennary N -glycan introduced at position N78 on the immune checkpoint TIM-3 (T cell immunoglobulin domain and mucin domain-containing molecule 3) on the interaction with a selective drug antagonist. The bulky N -glycan introduced at the consensus sequence Asn -Val-Thr has no influence on drug binding when the glycan adopts an extended conformation. But in a folded conformation, the glycan can interact directly with the triazoloquinazolinone derivative so as to further stabilize the drug-TIM-3 complex. The non-fucosylated glycan at position N78 markedly consolidates the drug interaction, via an additional H-bond interaction with the α3-mannose residue. It provides a gain of empirical potential energy of interaction (ΔE) of about 30 %. The presence of a more rigid fucosylated N -glycan is a little less favorable, with a gain of ΔE of about 20 %. The folded N -glycan appears to protect the ligand bound to the protein cavity, with the tricyclic core of the heterocyclic molecule sandwiched between two indole rings of tryptophan residues. Similar results were obtained when using a biantennary disialyl N -glycan with a bisecting GlcNAc residue and a tetra-antennary N -glycan. The molecular models illustrate the drug-stabilizing capacity of a bulky N -glycan positioned at a validated glycosylation site (N78 corresponding to N100 for the full-length protein). The modeling approach is useful to delineate further the role of the N -glycan of the immune checkpoint TIM-3 in interaction with small molecule ligands, and to guide the design of more potent compounds. The approach is transposable to other proteins to better comprehend the influence of N -glycans on drug-receptor interactions. Display Omitted • We have modeled the N -glycosylation of the immune checkpoint TIM-3. • Introduction of a bi-antennary N -glycan reinforces drug binding to a proximal site. • Incorporation of a bisecting GlcNAc or a tetra-antennary N -glycan consolidate drug binding. • This model system illustrates the contribution of a N -glycan to drug-protein interaction.